SuperworthEvommune EVMN
- Market cap
- $185.1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 18.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $10M
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −40.3%
Evommune trades at 18.5× sales. Revenue was $10M over the last twelve months.
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| n/a | $0 | $3M | $0 | $10M | $0 | $0 | $0 | |
| R&D | $13.3M | $17.8M | $14.4M | $19.6M | $19.6M+48% | $20.4M+14% | $17.3M+21% | $26.4M+35% |
| SG&A | $3.2M | $3.6M | $3.7M | $3.4M | $3.7M+14% | $9.3M+157% | $6.6M+81% | $8.5M+153% |
| −$16.5M | −$21.5M | −$15M | −$23M | −$13.3M−19% | −$29.7M+39% | −$24M+59% | −$34.9M+52% | |
| Net income | −$15.9M | −$20.7M | −$14.6M | −$13.6M | −$12.5M−22% | −$28.3M+36% | −$21.7M+49% | −$32.2M+138% |
| −$10.47 | −$14.54 | −$9.48 | −$8.80 | −$8.07−23% | n/a | −$0.64−93% | −$0.89−90% | |
| 1.5M | 1.5M | 1.5M | 1.5M | 1.5M+2% | n/a | 33.7M+2094% | 36.1M+2245% |
EPS, diluted: Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Evommune's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EVMNEvommune | $185.1M | n/m | n/a | 18.5× | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $523.1M | 11.3× | 13.6× | 1.4× | +7% | 11.6% |
More on Evommune
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .